Reach Us +1-217-403-9671
Bioavailability And Bioequivalence Of Novel Drug Delivery Systems | 8357
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Bioavailability and Bioequivalence of Novel Drug delivery systems

International Conference & Exhibition Bioequivalence and Bioavailability

Dr. N. Udupa

ScientificTracks Abstracts: Bioavailability & Bioequivalence

DOI: 10.4172/0975-0851.1000001

B ioavailability and bioequivalence are the widely used terminologies in any drug development and approval process. Mostly bioavailability studies, whether for a new or generic product will be conducted to identify the quantitative nature of a specific drug/product comparison. The comparison for a new drug may be to assess the performance of an oral dosage form relative to that of an intravenous dose, or perhaps the performance of a modified-release formulation in comparison to a conventional capsule. Similarly for generic product, it is often to compare new formulation with a reference/innovator product. Several factors which majorly effects the bioavailability are physiological/ pathological, physicochemical and dosage regimen considerations. Bioequivalence studies should be carried out when bio-inequivalence may have therapeutic significance. If a new formulation is intended to be a substitute for an approved formulation, the equivalence with this product should be shown or justified. The bioavailability and bioequivalence of the novel drug delivery systems are very challenging and great prospects are associated. In recent years there are several organizations working for the design of the regulatory guidelines in the areas of novel and targeted drug delivery systems